Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
153 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Synovial Sarcoma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H1 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape. Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 4 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Synovial Sarcoma - Overview Synovial Sarcoma - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Synovial Sarcoma - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Synovial Sarcoma - Companies Involved in Therapeutics Development Adaptimmune Therapeutics Plc Advenchen Laboratories LLC EpiZyme Inc Immune Design Corp Immunocore Ltd Johnson & Johnson Karyopharm Therapeutics Inc Merck & Co Inc Novartis AG OncoTherapy Science Inc Pfizer Inc Takara Bio Inc Synovial Sarcoma - Drug Profiles ACXT-3102 - Drug Profile Product Description Mechanism Of Action R&D Progress AL-3818 - Drug Profile Product Description Mechanism Of Action R&D Progress axitinib - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress CMB-305 - Drug Profile Product Description Mechanism Of Action R&D Progress CUE-102 - Drug Profile Product Description Mechanism Of Action R&D Progress everolimus - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-3377794 - Drug Profile Product Description Mechanism Of Action R&D Progress OTSA-101 - Drug Profile Product Description Mechanism Of Action R&D Progress pembrolizumab - Drug Profile Product Description Mechanism Of Action R&D Progress quisinostat hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress selinexor - Drug Profile Product Description Mechanism Of Action R&D Progress SSTC-104 - Drug Profile Product Description Mechanism Of Action R&D Progress tazemetostat - Drug Profile Product Description Mechanism Of Action R&D Progress TBI-1301 - Drug Profile Product Description Mechanism Of Action R&D Progress Synovial Sarcoma - Dormant Projects Synovial Sarcoma - Discontinued Products Synovial Sarcoma - Product Development Milestones Featured News & Press Releases Feb 22, 2016: The completion of phase I clinical study of the anti-cancer therapeutic antibody 'OTSA101'against synovial sarcoma Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Synovial Sarcoma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2017 Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, H1 2017 Synovial Sarcoma - Pipeline by EpiZyme Inc, H1 2017 Synovial Sarcoma - Pipeline by Immune Design Corp, H1 2017 Synovial Sarcoma - Pipeline by Immunocore Ltd, H1 2017 Synovial Sarcoma - Pipeline by Johnson & Johnson, H1 2017 Synovial Sarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017 Synovial Sarcoma - Pipeline by Merck & Co Inc, H1 2017 Synovial Sarcoma - Pipeline by Novartis AG, H1 2017 Synovial Sarcoma - Pipeline by OncoTherapy Science Inc, H1 2017 Synovial Sarcoma - Pipeline by Pfizer Inc, H1 2017 Synovial Sarcoma - Pipeline by Takara Bio Inc, H1 2017 Synovial Sarcoma - Dormant Projects, H1 2017 Synovial Sarcoma - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.